Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies

R. Tamm, R. Mägi, R. Tremmel, S. Winter, E. Mihailov, A. Smid, A. Möricke, K. Klein, M. Schrappe, M. Stanulla, R. Houlston, Richard M Weinshilboum, Irena Mlinarič Raščan, A. Metspalu, L. Milani, M. Schwab, E. Schaeffeler

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Thiopurine-related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases has been linked to genetically defined variability in thiopurine S-methyltransferase (TPMT) activity. While gene testing of TPMT is being clinically implemented, it is unclear if additional genetic variation influences TPMT activity with consequences for thiopurine-related toxicity. To examine this possibility, we performed a genome-wide association study (GWAS) of red blood cell TPMT activity in 844 Estonian individuals and 245 pediatric ALL cases. Additionally, we correlated genome-wide genotypes to human hepatic TPMT activity in 123 samples. Only genetic variants mapping to chromosome 6, including the TPMT gene region, were significantly associated with TPMT activity (P < 5.0 × 10-8) in each of the three GWAS and a joint meta-analysis of 1,212 cases (top hit P = 1.2 × 10-72). This finding is consistent with TPMT genotype being the primary determinant of TPMT activity, reinforcing the rationale for genetic testing of TPMT alleles in routine clinical practice to individualize mercaptopurine dosage.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - 2017

Fingerprint

thiopurine methyltransferase
Genome-Wide Association Study
Meta-Analysis
Phenotype
6-Mercaptopurine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genotype
Pediatrics
Chromosomes, Human, Pair 6
Genetic Testing

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Polymorphic variation in TPMT is the principal determinant of TPMT phenotype : A meta-analysis of three genome-wide association studies. / Tamm, R.; Mägi, R.; Tremmel, R.; Winter, S.; Mihailov, E.; Smid, A.; Möricke, A.; Klein, K.; Schrappe, M.; Stanulla, M.; Houlston, R.; Weinshilboum, Richard M; Mlinarič Raščan, Irena; Metspalu, A.; Milani, L.; Schwab, M.; Schaeffeler, E.

In: Clinical Pharmacology and Therapeutics, 2017.

Research output: Contribution to journalArticle

Tamm, R, Mägi, R, Tremmel, R, Winter, S, Mihailov, E, Smid, A, Möricke, A, Klein, K, Schrappe, M, Stanulla, M, Houlston, R, Weinshilboum, RM, Mlinarič Raščan, I, Metspalu, A, Milani, L, Schwab, M & Schaeffeler, E 2017, 'Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.540
Tamm, R. ; Mägi, R. ; Tremmel, R. ; Winter, S. ; Mihailov, E. ; Smid, A. ; Möricke, A. ; Klein, K. ; Schrappe, M. ; Stanulla, M. ; Houlston, R. ; Weinshilboum, Richard M ; Mlinarič Raščan, Irena ; Metspalu, A. ; Milani, L. ; Schwab, M. ; Schaeffeler, E. / Polymorphic variation in TPMT is the principal determinant of TPMT phenotype : A meta-analysis of three genome-wide association studies. In: Clinical Pharmacology and Therapeutics. 2017.
@article{8c565abc7dfc45c49c4d1836936cc3e7,
title = "Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies",
abstract = "Thiopurine-related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases has been linked to genetically defined variability in thiopurine S-methyltransferase (TPMT) activity. While gene testing of TPMT is being clinically implemented, it is unclear if additional genetic variation influences TPMT activity with consequences for thiopurine-related toxicity. To examine this possibility, we performed a genome-wide association study (GWAS) of red blood cell TPMT activity in 844 Estonian individuals and 245 pediatric ALL cases. Additionally, we correlated genome-wide genotypes to human hepatic TPMT activity in 123 samples. Only genetic variants mapping to chromosome 6, including the TPMT gene region, were significantly associated with TPMT activity (P < 5.0 × 10-8) in each of the three GWAS and a joint meta-analysis of 1,212 cases (top hit P = 1.2 × 10-72). This finding is consistent with TPMT genotype being the primary determinant of TPMT activity, reinforcing the rationale for genetic testing of TPMT alleles in routine clinical practice to individualize mercaptopurine dosage.",
author = "R. Tamm and R. M{\"a}gi and R. Tremmel and S. Winter and E. Mihailov and A. Smid and A. M{\"o}ricke and K. Klein and M. Schrappe and M. Stanulla and R. Houlston and Weinshilboum, {Richard M} and {Mlinarič Raščan}, Irena and A. Metspalu and L. Milani and M. Schwab and E. Schaeffeler",
year = "2017",
doi = "10.1002/cpt.540",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Polymorphic variation in TPMT is the principal determinant of TPMT phenotype

T2 - A meta-analysis of three genome-wide association studies

AU - Tamm, R.

AU - Mägi, R.

AU - Tremmel, R.

AU - Winter, S.

AU - Mihailov, E.

AU - Smid, A.

AU - Möricke, A.

AU - Klein, K.

AU - Schrappe, M.

AU - Stanulla, M.

AU - Houlston, R.

AU - Weinshilboum, Richard M

AU - Mlinarič Raščan, Irena

AU - Metspalu, A.

AU - Milani, L.

AU - Schwab, M.

AU - Schaeffeler, E.

PY - 2017

Y1 - 2017

N2 - Thiopurine-related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases has been linked to genetically defined variability in thiopurine S-methyltransferase (TPMT) activity. While gene testing of TPMT is being clinically implemented, it is unclear if additional genetic variation influences TPMT activity with consequences for thiopurine-related toxicity. To examine this possibility, we performed a genome-wide association study (GWAS) of red blood cell TPMT activity in 844 Estonian individuals and 245 pediatric ALL cases. Additionally, we correlated genome-wide genotypes to human hepatic TPMT activity in 123 samples. Only genetic variants mapping to chromosome 6, including the TPMT gene region, were significantly associated with TPMT activity (P < 5.0 × 10-8) in each of the three GWAS and a joint meta-analysis of 1,212 cases (top hit P = 1.2 × 10-72). This finding is consistent with TPMT genotype being the primary determinant of TPMT activity, reinforcing the rationale for genetic testing of TPMT alleles in routine clinical practice to individualize mercaptopurine dosage.

AB - Thiopurine-related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases has been linked to genetically defined variability in thiopurine S-methyltransferase (TPMT) activity. While gene testing of TPMT is being clinically implemented, it is unclear if additional genetic variation influences TPMT activity with consequences for thiopurine-related toxicity. To examine this possibility, we performed a genome-wide association study (GWAS) of red blood cell TPMT activity in 844 Estonian individuals and 245 pediatric ALL cases. Additionally, we correlated genome-wide genotypes to human hepatic TPMT activity in 123 samples. Only genetic variants mapping to chromosome 6, including the TPMT gene region, were significantly associated with TPMT activity (P < 5.0 × 10-8) in each of the three GWAS and a joint meta-analysis of 1,212 cases (top hit P = 1.2 × 10-72). This finding is consistent with TPMT genotype being the primary determinant of TPMT activity, reinforcing the rationale for genetic testing of TPMT alleles in routine clinical practice to individualize mercaptopurine dosage.

UR - http://www.scopus.com/inward/record.url?scp=85011255970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011255970&partnerID=8YFLogxK

U2 - 10.1002/cpt.540

DO - 10.1002/cpt.540

M3 - Article

C2 - 27770449

AN - SCOPUS:85011255970

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -